RxDoctor Payments Data

Steven Hill, DO

Family Medicine · South Bend, WANPI 1104875962

Payments from drug & device makers

$1,661in general payments, 2019–2025

Across 145 payments — averaging $11.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$715
  • Johnson & Johnson$262
  • AstraZeneca$175
  • Lilly USA, LLC$114
  • Boehringer Ingelheim$76
  • AbbVie$71
  • plus $248 from 8 others

What the payments were for

  • Food & beverage$1,63999%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,661 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$39,652
Medicare patients
97
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban327$225,426
JardianceEmpagliflozin154$102,898
XareltoRivaroxaban73$53,020
OzempicSemaglutide26$31,120
JanuviaSitagliptin Phosphate46$29,590
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$25,874
MounjaroTirzepatide17$22,482
FarxigaDapagliflozin Propanediol26$19,006
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen566$17,218
Bydureon BciseExenatide Microspheres18$16,125
TrulicityDulaglutide16$15,496
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$13,659
TradjentaLinagliptin15$11,269
EntrestoSacubitril/Valsartan15$9,842
Combivent RespimatIpratropium/Albuterol Sulfate13$7,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$715$229,741341 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Glyxambi$76$128,252194 claims
Johnson & JohnsonXarelto$262$53,02073 claims
Lilly USA, LLCMounjaro, Trulicity$114$37,97833 claims
Novo NordiskOzempic$23$31,12026 claims
AstraZenecaFarxiga$175$19,00626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in South Bend

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →